



# EUROSIN CAPITAL & V-NEXT SHENZHEN STOCK EXCHANGE

## LIFE-SCIENCE 2024 ROADSHOW

**Together with V-Next of ShenZhen Stock Exchange, Eurosine has selected 5 of our European-based Life-Science clients to present for a group of top-tier institutional Asian investors in a by-invitation-only online investment event.**

### Many Thanks to the Distinguished Guests:

- Zhu Hui, Investment Development Director of Sinopharm Group Co. Ltd. 国药控股股份有限公司.
- Sun Songting, General Manager, Shandong Haichuang Ceyuan Investment Co., Ltd. 山东海创策源投资有限公司.
  - Jiang Rouan, Financing Officer Y CAPITAL 旭医资本.
- Deng Bowen, Investment Manager of Shenzhen Capital Group Hongtu Private Equity Investment Fund Management (Shenzhen) Co., Ltd. 深创投红土私募股权投资基金管理（深圳）有限公司.
- Pu Zhuzhu, Project Operation Manager of Hanhai Zhiye Holding Group Co., Ltd. 瀚海智业控股集团有限公司.
  - Wang Bing, Investment Director of Tong Meng Capital 同盟投资（北京）有限公司.
- Li Shizong, Managing Director of Huashun Tiansheng Investment Management 华顺天盛（北京）投资管理有限公司.
  - Miku, Senior Partner of Japanese investment company 原本知名,
- Li Yankai, Business Manager of HeYu Capital Management. 和玉股权投资基金管理（天津）有限公司,
- Associate Director Shenzhen Dongfang Fuhai Venture Capital Management Co., Ltd. 深圳市东方富海创业投资管理有限公司
  - Tang Ziqing, Investment Director Cybernaut Investment Group Co., Ltd. 赛伯乐投资集团有限公司.
  - Yan An, Partner Techuangfa, 特创发（杭州）科技发展有限公司.
- Huang Wenbin, BD Investment Director of HiMed Angle Fund Management Co., Ltd. 上海海脉德创业投资管理有限公司,
- Wang Huiqi, Senior Manager of Aerospace Hi-Tech (Zhenjiang) Venture Capital Management Co., Ltd 航天高新（镇江）创业投资管理有限公司.
  - Huang Zhenguo, Business Development of Hangzhou Tigermed Consulting Co., Ltd. 泰格医药.
- Huang Rongquan, Head of Investment Operation of WEIGUANG LIFE SCIENCE PARK 卫光生命科学园公司
  - Ma Qiang, Business Developer of HangZhou Ruigu Medtech 杭州锐谷医疗技术有限公司.
  - Liu Xing, Investment Director of Greenland Holdings Corporation Limited 绿地集团.
    - Chen Han of Investment Manager Quan Lei Capital, 全垒资本
    - Chen Da, Industrial Operation Director of GLP Pte.Ltd. 兴航普洛斯



# PRESENTING COMPANIES

## EUROSIN CLIENTS

### **Sigrid Therapeutics**

Sigrid Therapeutics AB (Sigrid) was founded in 2014 by Prof. Tore Bengtsson and Ms. Sana Alajmovic, with the vision of transforming the way to prevent and treat our modern day chronic lifestyle diseases. The Company has since then developed a novel materials platform technology, SiPore™, which targets lifestyle diseases by changing the way our bodies digest food. The lead product candidate, SiPore15™, is being developed as the first therapy acting in the gut to improve blood sugar levels in people at risk of developing diabetes.



### **OncoZenge**

Potential to be the leading Treatment for Oral Pain, OncoZenge's leading product is BupiZenge™ contains the effective non-opioid long acting reliever bupivacaine. By applying bupivacaine in a lozenge the team is able to effectively relieve pain locally in the mouth and throat which solves this unmet medical need. Studies of BupiZenge™ has shown significant pain relief within minutes and lasting for hours.



### **AI Medical Technologies**

AI Medical Technology is a company operating in the interdisciplinary fields of data science, software development, and medicine. Founded by a diverse team of driven, passionate tech entrepreneurs, software developers and clinicians, AI Medical Technologies are dedicated to developing AI powered diagnostic solutions that enable frontline healthcare practitioners to make easier, faster, more cost effective and more reliable diagnoses for their patients.





# PRESENTING COMPANIES


## EUROSIN CLIENTS

### Single Cell Technologies

Single-Cell Technologies has 2 R&D laboratories and experimental centers. Their products include:

- analytics software (BIAS)
- Imaging (MICROS)
- single-cell LIMS system (SCIMS)
- cancer patient service platform (DRP)
- diagnostics platforms (mAlskin)
- 3D screening platform

SCT has 8 patents, an ethical permit and 500 melanoma patients, and 50.000 whole slide image with metadata.



### Real Heart

Realheart is the world's first four-chamber artificial heart is designed to be efficient, quiet, and lightweight to ensure that patients can live comfortably with high freedom of movement. The system is also designed with the medical procedure in mind to make the surgical implantations as simple as possible. Today, research is carried out in close collaboration with world-leading heart surgeons, international researchers, and engineers and interest from the world of research is constantly growing.



### Big Thank You to All Participants!!

Special Thanks to V-Next Platform for providing live translation and logistics, and the excellent presenters:

**Sana Alajmovic**, CEO of Sigrid Therapeutics  
**Stian Kildal**, CEO OncoZenge  
**Christoffer Ekström**, CEO of Ai Medical Technology  
**Peter Horvath**, CEO of Single-Cell-Technologies  
**Ina Laura Perkins**, CEO of Real Heart